JP2012532859A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532859A5
JP2012532859A5 JP2012519080A JP2012519080A JP2012532859A5 JP 2012532859 A5 JP2012532859 A5 JP 2012532859A5 JP 2012519080 A JP2012519080 A JP 2012519080A JP 2012519080 A JP2012519080 A JP 2012519080A JP 2012532859 A5 JP2012532859 A5 JP 2012532859A5
Authority
JP
Japan
Prior art keywords
cells
fibroblasts
regulatory
stem cells
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532859A (ja
JP5892931B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/001968 external-priority patent/WO2011004264A1/en
Publication of JP2012532859A publication Critical patent/JP2012532859A/ja
Publication of JP2012532859A5 publication Critical patent/JP2012532859A5/ja
Application granted granted Critical
Publication of JP5892931B2 publication Critical patent/JP5892931B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519080A 2009-07-09 2010-07-09 細胞治療において使用するための方法および組成物 Active JP5892931B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22427509P 2009-07-09 2009-07-09
US61/224,275 2009-07-09
PCT/IB2010/001968 WO2011004264A1 (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Publications (3)

Publication Number Publication Date
JP2012532859A JP2012532859A (ja) 2012-12-20
JP2012532859A5 true JP2012532859A5 (enExample) 2013-08-15
JP5892931B2 JP5892931B2 (ja) 2016-03-23

Family

ID=42782196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519080A Active JP5892931B2 (ja) 2009-07-09 2010-07-09 細胞治療において使用するための方法および組成物

Country Status (19)

Country Link
US (1) US8679834B2 (enExample)
EP (2) EP3150703A1 (enExample)
JP (1) JP5892931B2 (enExample)
KR (1) KR101788885B1 (enExample)
CN (2) CN102549147A (enExample)
AU (1) AU2010269962B2 (enExample)
BR (1) BR112012000534A2 (enExample)
CA (1) CA2767300C (enExample)
DK (1) DK2451943T3 (enExample)
ES (1) ES2479542T3 (enExample)
HU (1) HUE031921T2 (enExample)
IL (1) IL217377A (enExample)
MX (1) MX359639B (enExample)
NZ (1) NZ597975A (enExample)
PL (1) PL2451943T3 (enExample)
PT (1) PT2451943T (enExample)
RU (1) RU2610427C2 (enExample)
SG (2) SG177582A1 (enExample)
WO (1) WO2011004264A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
WO2011006029A1 (en) 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
US11090363B2 (en) 2009-07-10 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Vasoactive intestinal peptide release from microparticles
ES2479544T1 (es) * 2011-01-12 2014-08-20 Tigenix, S.A.U. Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA2857545A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
EP2833896A2 (en) * 2012-03-30 2015-02-11 University Of Southern California Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US10258652B2 (en) 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
WO2016107563A1 (zh) * 2014-12-29 2016-07-07 西比曼生物科技(上海)有限公司 一种用于治疗上呼吸道疾病的脂肪间充质祖细胞复合物
WO2016151476A1 (en) 2015-03-23 2016-09-29 Pluristem Ltd. Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof
US20210205370A1 (en) 2016-02-18 2021-07-08 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
EP3478300B1 (en) 2016-06-30 2022-08-24 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3624815A4 (en) 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
EP3624816A4 (en) 2017-05-15 2021-02-24 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH STEM CELLS DERIVED FROM ADIPOUS TISSUE
CN107349419A (zh) * 2017-07-17 2017-11-17 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
CN107281469A (zh) * 2017-07-17 2017-10-24 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
CN112912087A (zh) 2018-09-14 2021-06-04 卢卡科学株式会社 线粒体向淋巴器官中的移植以及用于该移植的组合物
WO2020191036A1 (en) * 2019-03-19 2020-09-24 Fibrogenesis Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
WO2020243504A1 (en) * 2019-05-31 2020-12-03 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
WO2021207192A1 (en) * 2020-04-08 2021-10-14 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800113C (en) * 2002-07-12 2015-02-03 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
ES2354944T3 (es) * 2002-12-06 2011-03-21 Northwest Biotherapeutics, Inc. Administración de células dendríticas maduradas parcialmente in vitro para el tratamiento de tumores.
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
EP2578677A1 (en) * 2007-08-09 2013-04-10 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009031606A1 (ja) * 2007-09-07 2009-03-12 Jcr Pharmaceuticals Co., Ltd. 関節炎治療及び予防剤
US20110150845A1 (en) * 2008-05-02 2011-06-23 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells

Similar Documents

Publication Publication Date Title
JP2012532859A5 (enExample)
RU2012104529A (ru) Способы и композиции для применения в клеточной терапии
Julier et al. Promoting tissue regeneration by modulating the immune system
Gao et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure
ES2479544T1 (es) Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias
JP2014502628A5 (enExample)
EA201691347A2 (ru) Терапия глатирамером ацетатом с низкой кратностью
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
MX2010003019A (es) Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
JP2014528901A5 (enExample)
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
RU2013123646A (ru) Комбинированная композиция
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
RU2014122858A (ru) Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями
Wen et al. Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
RU2012136724A (ru) Лечение или профилактика инфекции
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
Millar et al. Frozen shoulder (Primer)